4
Changes in Ownership
4D Molecular Therapeutics, Inc. Filed Acc 0000950170-24-062637
Chief Legal Officer sold 1,750 shares at an average $25.45 ($44,541)
- Chief Legal Officer acquired 1,750 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bizily Scott Chief Legal Officer | 2024-05-16 | Option exercise 10b5-1 | +500 | $6.49 | $3,245 | 2,237 | D |
| Bizily Scott Chief Legal Officer | 2024-05-16 | Option exercise 10b5-1 | +1,250 | $8.04 | $10,050 | 3,487 | D |
| Bizily Scott Chief Legal Officer | 2024-05-16 | Sale 10b5-1 | −1,283 | $25.34 | $32,514 | 2,204 | D |
| Bizily Scott Chief Legal Officer | 2024-05-16 | Sale 10b5-1 | −467 | $25.75 | $12,027 | 1,737 | D |
| Derivatives | |||||||
| Bizily Scott Chief Legal Officer | 2024-05-16 | Option exercise · Stock Option (Right To Buy) 10b5-1 | −500 | 13,711 | D | ||
| Bizily Scott Chief Legal Officer | 2024-05-16 | Option exercise · Stock Option (Right To Buy) 10b5-1 | −1,250 | 37,918 | D | ||
| Open-market sales · 1,750 sh · avg $25.45 · $44,541 | |||||||
Loading xslF345X05/ownership.xml…